uniQure N.V., a biopharmaceutical company, develops adeno-associated virus (AAV) based gene therapies through its technology platform for multiple therapeutic areas. The company offers Glybera for the treatment of patients with lipoprotein lipase deficiency. It also develops AMT-060, a gene therapy that is in Phase I/II clinical trial for the treatment of hemophilia B; S100A1, a preclinical therapeutic for congestive heart failure; AMT-021, a gene therapy, which has completed Phase I clinical trial for acute intermittent porphyria; AMT-110, a gene therapy that is in Phase I/II clinical trial for Sanfilippo B syndrome; and AAV2/glial cell line-derived neurotrophic factor for Parkinson's disease. The company has collaborations with Chiesi Farmaceutici S.p.A., Digna Biotech, Institut Pasteur, University of California San Francisco, Bristol-Myers Squibb, and 4D Molecular Therapeutics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
March 4, 2021
RegMed Investors’ (RMi) closing bell: the hole got deeper and bottoms became steeper
March 2, 2021
RegMed Investors’ (RMi) closing bell: some say volatility has resurfaced, I had said it never left
March 2, 2021
RegMed Investors’ (RMi) pre-open: a case of investing interruptus from the previous session?
March 1, 2021
RegMed Investors’ (RMi) closing bell: sector rebounds after a tough February
February 26, 2021
RegMed Investors’ (RMi) closing bell: telling a sector story with daily data
February 26, 2021
RegMed Investors’ (RMi) pre-open: momentum and resistance, the cause and causation of the month’s last session
February 25, 2021
RegMed Investors’ (RMi) closing bell: the sector’s pricing vomited most upsides during frothy moves
February 24, 2021
RegMed Investors’ (RMi) closing bell: volatility provides a comeback
February 24, 2021
RegMed Investors’ (RMi) pre-open: a bounce, a pounce or just an ounce of upside needed
February 23, 2021
RegMed Investors’ (RMi) closing bell: a pullback, a reversal, a retest or in many cases just plain old earnings’ season doldrums?
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors